Home › Companies › GLSI

Greenwich LifeSciences

GLSI Lead: Phase 3 ★ Read the deep dive → 9 Biotech Distilled articles ↓

Oncology Peptide

Most recent annual filing: 2026-06-01

Pipeline (1 active programs)

GP2

GLSI-100

Peptide Target: HER2/neu, GP2

Breast Cancer Phase 3 intradermal

Biotech Distilled coverage (9)

2026-06-04 UPDATE: Greenwich LifeSciences (GLSI) — The 10-Q Decodes the 17% Drop
2026-06-02 UPDATE: Greenwich LifeSciences (GLSI) — The 10-K Lands, ASCO Confirms the Mechanism 🔒 Paid
2026-04-27 UPDATE: Greenwich LifeSciences (GLSI) — The Protocol Pivot, the Patent Stretch, and a Late 10-K 🔒 Paid
2026-03-22 UPDATE: Greenwich LifeSciences (GLSI) - The Data Firehose 🔒 Paid
2026-03-07 UPDATE: Greenwich LifeSciences (GLSI) - Foot on the Gas. Screening Rate Jumps 33%. 🔒 Paid
2026-02-28 UPDATE: Greenwich LifeSciences (GLSI) - Mark Your Calendars. The Steering Committee Speaks. 🔒 Paid
2026-01-30 UPDATE: Greenwich Lifesciences (GLSI) - The ATM Just Printed $7 Million. Is the Cash Crunch Over? 🔒 Paid
2026-01-25 Update: Greenwich LifeSciences (GLSI) - The Boring News That Actually Matters 🔒 Paid
2025-12-26 Greenwich LifeSciences (GLSI): Scientific Due Diligence for GLSI-100

Articles open on Substack. Some deep dives are subscriber-only.